Natural killer cells and engagers: Powerful weapons against cancer.
NK cell engagers
cancer
human NK cells
immunotherapies
Journal
Immunological reviews
ISSN: 1600-065X
Titre abrégé: Immunol Rev
Pays: England
ID NLM: 7702118
Informations de publication
Date de publication:
24 Aug 2024
24 Aug 2024
Historique:
medline:
24
8
2024
pubmed:
24
8
2024
entrez:
24
8
2024
Statut:
aheadofprint
Résumé
Natural killer (NK) cells are innate immune effectors whose functions rely on receptors binding cytokines, recognizing self-molecules, or detecting danger signals expressed by virus-infected or tumor cells. The potent cytotoxic potential makes NK cells promising candidates for cancer immunotherapy. To enhance their activity strategies include cytokine administration, blocking of immune checkpoints, and designing of antibody-based NK cell engagers (NKCEs). NKCEs represent a cutting-edge approach to cancer therapy: they strengthen the NK-to-target cell interactions and optimize tumor killing, possibly overcoming the immunosuppressive tumor microenvironment. NK cells belong to the innate lymphoid cells (ILCs) and are categorized into different subsets also including cells with a memory-like phenotype: this complexity needs to be explored in the context of cancer immunotherapy, particularly when designing NKCEs. Two strategies to enhance NK cell activity in cancer patients can be adopted: activating patients' own NK cells versus the adoptive transfer of ex vivo activated NK cells. Furthermore, the capability of NKCEs to activate γδ T cells could have a significant synergistic effect in immunotherapy.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agence Nationale de la Recherche, PIONEER Project
ID : ANR-17-RHUS-0007
Organisme : Ministero della Salute, 5x1000 grants
ID : project 5M-2018-23680422
Organisme : European Research Council (ERC), TREATLIVMETS
ID : 101118936
Informations de copyright
© 2024 The Author(s). Immunological Reviews published by John Wiley & Sons Ltd.
Références
Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell‐mediated effector immunity. J Allergy Clin Immunol. 2015;135(3):626‐635. doi:10.1016/j.jaci.2014.11.001
Lanier LL. Five decades of natural killer cell discovery. J Exp Med. 2024;221(8):e20231222. doi:10.1084/jem.20231222
Aguilar OA, Fong L, Lanier LL. ITAM ‐based receptors in natural killer cells. Immunol Rev. 2024;323(1):40‐53. doi:10.1111/imr.13313
Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell‐mediated cytolysis. Annu Rev Immunol. 2001;19(1):197‐223. doi:10.1146/annurev.immunol.19.1.197
Ljunggren HG, Kärre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today. 1990;11:237‐244. doi:10.1016/0167-5699(90)90097-S
Wroblewski EE, Parham P, Guethlein LA. Two to tango: Co‐evolution of hominid natural killer cell receptors and MHC. Front Immunol. 2019;10:177. doi:10.3389/fimmu.2019.00177
Moretta A, Bottino C, Vitale M, et al. Receptors for HLA class‐I molecules in human natural killer cells. Annu Rev Immunol. 1996;14(1):619‐648. doi:10.1146/annurev.immunol.14.1.619
López‐Botet M, Llano M, Navarro F, Bellon T. NK cell recognition of non‐classical HLA class I molecules. Semin Immunol. 2000;12(2):109‐119. doi:10.1006/smim.2000.0213
Braud VM, Allan DSJ, O'Callaghan CA, et al. HLA‐E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391(6669):795‐799. doi:10.1038/35869
Cosman D, Fanger N, Borges L, et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity. 1997;7(2):273‐282. doi:10.1016/S1074-7613(00)80529-4
Orr MT, Lanier LL. Natural killer cell education and tolerance. Cell. 2010;142(6):847‐856. doi:10.1016/j.cell.2010.08.031
Leijonhufvud C, Reger R, Segerberg F, et al. LIR‐1 educates expanded human NK cells and defines a unique antitumor NK cell subset with potent antibody‐dependent cellular cytotoxicity. Clin Transl Immunology. 2021;10(10):e1346. doi:10.1002/cti2.1346
Rückert T, Romagnani C. Extrinsic and intrinsic drivers of natural killer cell clonality. Immunol Rev. 2024;323(1):80‐106. doi:10.1111/imr.13324
Vuscan P, Kischkel B, Joosten LAB, Netea MG. Trained immunity: general and emerging concepts. Immunol Rev. 2024;323(1):164‐185. doi:10.1111/imr.13326
Bellora F, Castriconi R, Dondero A, et al. The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. Proc Natl Acad Sci USA. 2010;107(50):21659‐21664. doi:10.1073/pnas.1007654108
Ferlazzo G, Moretta L. Dendritic cell editing by natural killer cells. Crit Rev Oncog. 2014;19(1–2):67‐75. doi:10.1615/CritRevOncog.2014010827
Merli P, Algeri M, Galaverna F, et al. TCRαβ/CD19 cell–depleted HLA‐haploidentical transplantation to treat pediatric acute leukemia: updated final analysis. Blood. 2024;143(3):279‐289. doi:10.1182/blood.2023021336
Briukhovetska D, Dörr J, Endres S, Libby P, Dinarello CA, Kobold S. Interleukins in cancer: from biology to therapy. Nat Rev Cancer. 2021;21(8):481‐499. doi:10.1038/s41568-021-00363-z
Kulhanek KR, Kalbasi A. Targeted bias: the next swing at IL2 therapy. Cancer Discov. 2024;14(7):1145‐1146. doi:10.1158/2159-8290.CD-24-0558
Vivier E, Rebuffet L, Narni‐Mancinelli E, Cornen S, Igarashi RY, Fantin VR. Natural killer cell therapies. Nature. 2024;626(8000):727‐736. doi:10.1038/s41586-023-06945-1
Marrella A, Dondero A, Aiello M, et al. Cell‐laden hydrogel as a clinical‐relevant 3D model for analyzing neuroblastoma growth, immunophenotype, and susceptibility to therapies. Front Immunol. 2019;10:1876. doi:10.3389/fimmu.2019.01876
Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. FcγRIIIa‐158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa‐48L/R/H phenotype. Blood. 1997;90(3):1109‐1114. doi:10.1182/blood.V90.3.1109
Marshall MJE, Stopforth RJ, Cragg MS. Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going? Front Immunol. 2017;8:1245. doi:10.3389/fimmu.2017.01245
Bottino C, Dondero A, Bellora F, et al. Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches. Front Immunol. 2014;5:5. doi:10.3389/fimmu.2014.00056
Zhang M, Lam KP, Xu S. Natural killer cell engagers (NKCEs): a new frontier in cancer immunotherapy. Front Immunol. 2023;14:1207276. doi:10.3389/fimmu.2023.1207276
Pyzik M, Sand KMK, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS. The neonatal fc receptor (FcRn): a misnomer? Front Immunol. 2019;10:1540. doi:10.3389/fimmu.2019.01540
Blumberg RS, Lillicrap D, the IgG Fc Immune Tolerance Group. Tolerogenic properties of the fc portion of IgG and its relevance to the treatment and management of hemophilia. Blood. 2018;131(20):2205‐2214. doi:10.1182/blood-2017-12-822908
Arvindam US, Van Hauten PMM, Schirm D, et al. A trispecific killer engager molecule against CLEC12A effectively induces NK‐cell mediated killing of AML cells. Leukemia. 2021;35(6):1586‐1596. doi:10.1038/s41375-020-01065-5
Asaadi Y, Jouneghani FF, Janani S, Rahbarizadeh F. A comprehensive comparison between camelid nanobodies and single chain variable fragments. Biomark Res. 2021;9(1):87. doi:10.1186/s40364-021-00332-6
Ye QN, Zhu L, Liang J, et al. Orchestrating NK and T cells via tri‐specific nano‐antibodies for synergistic antitumor immunity. Nat Commun. 2024;15(1):6211. doi:10.1038/s41467-024-50474-y
Gauthier L, Virone‐Oddos A, Beninga J, et al. Control of acute myeloid leukemia by a trifunctional NKp46‐CD16a‐NK cell engager targeting CD123. Nat Biotechnol. 2023;41(9):1296‐1306. doi:10.1038/s41587-022-01626-2
Demaria O, Gauthier L, Vetizou M, et al. Antitumor immunity induced by antibody‐based natural killer cell engager therapeutics armed with not‐alpha IL‐2 variant. Cell Reports Medicine. 2022;3(10):100783. doi:10.1016/j.xcrm.2022.100783
Dondero A, Morini M, Cangelosi D, et al. Multiparametric flow cytometry highlights B7‐H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants. J Immunother Cancer. 2021;9(4):e002293. doi:10.1136/jitc-2020-002293
Castriconi R, Dondero A, Augugliaro R, et al. Identification of 4Ig‐B7‐H3 as a neuroblastoma‐associated molecule that exerts a protective role from an NK cell‐mediated lysis. Proc Natl Acad Sci USA. 2004;101(34):12640‐12645. doi:10.1073/pnas.0405025101
Bottino C, Della Chiesa M, Sorrentino S, et al. Strategies for potentiating NK‐mediated neuroblastoma surveillance in autologous or HLA‐haploidentical hematopoietic stem cell transplants. Cancer. 2022;14(19):4548. doi:10.3390/cancers14194548
Gregorio A, Corrias MV, Castriconi R, et al. Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7‐H3 surface molecule. Histopathology. 2008;53(1):73‐80. doi:10.1111/j.1365-2559.2008.03070.x
Bottino C, Vitale C, Dondero A, Castriconi R. B7‐H3 in pediatric tumors: far beyond neuroblastoma. Cancer. 2023;15(13):3279. doi:10.3390/cancers15133279
Vivier E, Rebuffet L, Melsen J, et al. High‐Dimensional Single‐Cell Analysis of Natural Killer Cell Heterogeneity in Human Blood. 2024. doi:10.21203/rs.3.rs-3870228/v1
Müller NC, Romagnani C. To kill or not to kill—the role of the tumor microenvironment in shaping group 1 ILC functions. Semin Immunol. 2022;61‐64:101670. doi:10.1016/j.smim.2022.101670
Ding Y, Lavaert M, Grassmann S, et al. Distinct developmental pathways generate functionally distinct populations of natural killer cells. Nat Immunol. 2024;13:1183‐1192. doi:10.1038/s41590-024-01865-2
Worthington JJ, Klementowicz JE, Travis MA. TGFβ: a sleeping giant awoken by integrins. Trends Biochem Sci. 2011;36(1):47‐54. doi:10.1016/j.tibs.2010.08.002
Hawke LG, Whitford MKM, Ormiston ML. The production of pro‐angiogenic VEGF‐A isoforms by hypoxic human NK cells is independent of their TGF‐β‐mediated conversion to an ILC1‐like phenotype. Front Immunol. 2020;11:1903. doi:10.3389/fimmu.2020.01903
Kansler ER, Dadi S, Krishna C, et al. Cytotoxic innate lymphoid cells sense cancer cell‐expressed interleukin‐15 to suppress human and murine malignancies. Nat Immunol. 2022;23(6):904‐915. doi:10.1038/s41590-022-01213-2
Sen Santara S, Lee DJ, Crespo Â, et al. The NK cell receptor NKp46 recognizes ecto‐calreticulin on ER‐stressed cells. Nature. 2023;616(7956):348‐356. doi:10.1038/s41586-023-05912-0
Jost S, Lucar O, Lee E, et al. Antigen‐specific memory NK cell responses against HIV and influenza use the NKG2/HLA‐E axis. Sci Immunol. 2023;8(90):eadi3974. doi:10.1126/sciimmunol.adi3974
López‐Botet M, De Maria A, Muntasell A, Della Chiesa M, Vilches C. Adaptive NK cell response to human cytomegalovirus: facts and open issues. Semin Immunol. 2023;65:101706. doi:10.1016/j.smim.2022.101706
Wijaya RS, Read SA, Truong NR, et al. HBV vaccination and HBV infection induces HBV‐specific natural killer cell memory. Gut. 2020;70:357‐369. doi:10.1136/gutjnl-2019-319252
Gumá M, Angulo A, Vilches C, Gómez‐Lozano N, Malats N, López‐Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood. 2004;104(12):3664‐3671. doi:10.1182/blood-2004-05-2058
Hammer Q, Rückert T, Borst EM, et al. Peptide‐specific recognition of human cytomegalovirus strains controls adaptive natural killer cells. Nat Immunol. 2018;19(5):453‐463. doi:10.1038/s41590-018-0082-6
Gamliel M, Goldman‐Wohl D, Isaacson B, et al. Trained memory of human uterine NK cells enhances their function in subsequent pregnancies. Immunity. 2018;48(5):951‐962. doi:10.1016/j.immuni.2018.03.030
Rückert T, Lareau CA, Mashreghi MF, Ludwig LS, Romagnani C. Clonal expansion and epigenetic inheritance of long‐lasting NK cell memory. Nat Immunol. 2022;23(11):1551‐1563. doi:10.1038/s41590-022-01327-7
Sarhan D, Hippen KL, Lemire A, et al. Adaptive NK cells resist regulatory T‐cell suppression driven by IL37. Cancer Immunol Res. 2018;6(7):766‐775. doi:10.1158/2326-6066.CIR-17-0498
Sarhan D, Cichocki F, Zhang B, et al. Adaptive NK cells with low TIGIT expression are inherently resistant to myeloid‐derived suppressor cells. Cancer Res. 2016;76(19):5696‐5706. doi:10.1158/0008-5472.CAN-16-0839
Queirolo P, Boutros A, Tanda E, Spagnolo F, Quaglino P. Immune‐checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. Semin Cancer Biol. 2019;59:290‐297. doi:10.1016/j.semcancer.2019.08.001
Dondero A, Pastorino F, Della Chiesa M, et al. PD‐L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. Onco Targets Ther. 2016;5(1):e1064578. doi:10.1080/2162402X.2015.1064578
Lei Q, Wang D, Sun K, Wang L, Zhang Y. Resistance mechanisms of anti‐PD1/PDL1 therapy in solid tumors. Front Cell Dev Biol. 2020;8:672. doi:10.3389/fcell.2020.00672
Profaci CP, Munji RN, Pulido RS, Daneman R. The blood–brain barrier in health and disease: important unanswered questions. J Exp Med. 2020;217(4):e20190062. doi:10.1084/jem.20190062
Van De Walle T, Vaccaro A, Ramachandran M, Pietilä I, Essand M, Dimberg A. Tertiary lymphoid structures in the central nervous system: implications for glioblastoma. Front Immunol. 2021;12:724739. doi:10.3389/fimmu.2021.724739
Wang S, Van De Pavert SA. Innate lymphoid cells in the central nervous system. Front Immunol. 2022;13:837250. doi:10.3389/fimmu.2022.837250
Ren F, Zhao Q, Huang L, et al. The R132H mutation in IDH 1 promotes the recruitment of NK cells through CX 3 CL 1/ CX 3 CR 1 chemotaxis and is correlated with a better prognosis in gliomas. Immunol Cell Biol. 2019;97(5):457‐469. doi:10.1111/imcb.12225
Locatelli F, Merli P, Pagliara D, et al. Outcome of children with acute leukemia given HLA‐haploidentical HSCT after αβ T‐cell and B‐cell depletion. Blood. 2017;130(5):677‐685. doi:10.1182/blood-2017-04-779769
Flaadt T, Ebinger M, Schreiber M, et al. Multimodal therapy with consolidating haploidentical stem cell transplantation and Dinutuximab Beta for patients with high‐risk neuroblastoma and central nervous system relapse. J Clin Med. 2023;12(19):6196. doi:10.3390/jcm12196196
Pende D, Falco M, Vitale M, et al. Killer Ig‐like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation. Front Immunol. 2019;10:1179. doi:10.3389/fimmu.2019.01179
Oberschmidt O, Morgan M, Huppert V, et al. Development of automated separation, expansion, and quality control protocols for clinical‐scale manufacturing of primary human NK cells and Alpharetroviral chimeric antigen receptor engineering. Hum Gene Ther Methods. 2019;30(3):102‐120. doi:10.1089/hgtb.2019.039
Tanzi M, Consonni M, Falco M, et al. Cytokine‐induced memory‐like NK cells with high reactivity against acute leukemia blasts and solid tumor cells suitable for adoptive immunotherapy approaches. Cancer. 2021;13(7):1577. doi:10.3390/cancers13071577
Mensurado S, Blanco‐Domínguez R, Silva‐Santos B. The emerging roles of γδ T cells in cancer immunotherapy. Nat Rev Clin Oncol. 2023;20(3):178‐191. doi:10.1038/s41571-022-00722-1
Arias‐Badia M, Chang R, Fong L. γδ T cells as critical anti‐tumor immune effectors. Nat Can. 2024. doi:10.1038/s43018-024-00798-x Epub ahead of print.
Mikulak J, Oriolo F, Bruni E, et al. NKp46‐expressing human gut‐resident intraepithelial Vδ1 T cell subpopulation exhibits high antitumor activity against colorectal cancer. JCI Insight. 2019;4(24):e125884. doi:10.1172/jci.insight.125884
Maniar A, Zhang X, Lin W, et al. Human γδ T lymphocytes induce robust NK cell–mediated antitumor cytotoxicity through CD137 engagement. Blood. 2010;116(10):1726‐1733. doi:10.1182/blood-2009-07-234211
De Gassart A, Le KS, Brune P, et al. Development of ICT01, a first‐in‐class, anti‐BTN3A antibody for activating Vγ9Vδ2 T cell–mediated antitumor immune response. Sci Transl Med. 2021;13(616):eabj0835. doi:10.1126/scitranslmed.abj0835
Bold A, Gross H, Holzmann E, Knop S, Hoeres T, Wilhelm M. An optimized cultivation method for future in vivo application of γδ T cells. Front Immunol. 2023;14:1185564. doi:10.3389/fimmu.2023.1185564
Nelson A, Lukacs JD, Johnston B. The current landscape of NKT cell immunotherapy and the hills ahead. Cancer. 2021;13(20):5174. doi:10.3390/cancers13205174